CHMP Backs Bexsero Booster Dose – GSK’s MenB Vaccine Label Update Recommended for Individuals Aged 10 Years and Older

Fineline Cube
4 Min Read
Summarize with AI

GlaxoSmithKline Plc (GSK) (NYSE: GSK) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended updating the Bexsero (4CMenB) label to include a single booster dose for individuals aged 10 years and older who were previously vaccinated at least two years earlier with Bexsero. The positive opinion positions GSK to extend protection against Invasive Meningococcal Disease (IMD) caused by Neisseria meningitidis serogroup B (MenB) well beyond the primary infant series.

- Advertisement -

Regulatory Milestone

ItemDetail
AgencyCHMP / EMA (European Union)
Recommendation TypePositive opinion on label update (booster dosing)
ProductBexsero (4CMenB), recombinant multicomponent MenB vaccine
Proposed Label ChangeSingle booster dose for individuals aged ≥10 years, vaccinated ≥2 years previously with Bexsero
Announcement Date14 November 2026
Next StepsEuropean Commission final decision on the label update, expected in due course following the CHMP opinion

Drug Profile & Mechanism of Action

  • Molecule: Bexsero (4CMenB) – a recombinant, multicomponent vaccine combining multiple MenB antigens (factor H binding protein, Neisserial adhesin A, NHBA fusion protein, and outer membrane vesicles) to elicit broad immune coverage against serogroup B strains.
  • Target Pathogen: Neisseria meningitidis serogroup B, a leading bacterial cause of meningitis and sepsis, with adolescents and young adults among the age groups at elevated carriage and transmission risk.
  • Global Footprint: Registered in 61 countries for the prevention of IMD caused by MenB.
  • Clinical Differentiator: Demonstrated persistence of immune memory up to 19 years after infant primary vaccination, revivable with a single booster dose – addressing the known challenge of waning antibody levels after the primary series.

Clinical Evidence – Phase 3b Study (Men‑B‑096)

EndpointResultComparatorRelative Benefit
Study DesignSingle Bexsero booster dose in healthy individuals aged 10–20 years who previously completed the Bexsero primary series––
ImmunogenicityImmune memory established by infant primary vaccination successfully boosted by a single dose up to 19 years later–Sustained protection potential
Safety & ReactogenicityConsistent with the known safety profile of Bexsero in this age group–Favorable tolerability
Numerical Endpoint DataNot disclosedNot disclosedNot disclosed

The Men‑B‑096 study, a Phase 3b trial in healthy adolescents and young adults aged 10–20 years, assessed the immune response and safety of a single booster dose administered after prior completion of the Bexsero primary vaccination series. The trial formed the evidentiary basis for the CHMP’s positive opinion; specific immunogenicity values and endpoint magnitudes were not disclosed in the announcement.

Market Impact & Outlook

  • Franchise Extension: The recommended label update would unlock a booster-dosing revenue stream across a large cohort of individuals originally vaccinated in infancy, materially expanding Bexsero’s addressable population without a new clinical indication.
  • Public Health Positioning: With immune memory demonstrable up to 19 years post-primary series, the booster supports potential incorporation into adolescent immunization programs and national MenB policy discussions across the EU’s 61-country registered footprint.
  • Competitive Landscape: MenB vaccination remains a duopoly market; a booster-inclusive label would give Bexsero a differentiated lifecycle advantage in tender and national immunization negotiations.
  • Safety Profile Consistency: Reactogenicity consistent with Bexsero’s established profile lowers adoption barriers among physicians and public health authorities considering catch-up and booster campaigns.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, clinical outcomes, and commercial expectations for Bexsero, including the anticipated European Commission decision following the CHMP opinion. Actual results may differ due to risks including final regulatory determinations, label wording, national immunization policy decisions, market adoption, and competitive dynamics.-Fineline Info & Tech

Share This Article
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *